BRD4-BD1-IN-2

CAS No. 2761321-26-8

BRD4-BD1-IN-2( —— )

Catalog No. M35765 CAS No. 2761321-26-8

BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 387 In Stock
10MG 471 In Stock
25MG 630 In Stock
50MG 768 In Stock
100MG 977 In Stock
200MG 1283 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BRD4-BD1-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.
  • Description
    BRD4-BD1-IN-2 is a selective BRD4-BD1 inhibitor, with an IC50 of 2.51 μM (20-times greater than that of BD2). BRD4-BD1-IN-2 can be used in studies of cancer and cardiovascular diseases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2761321-26-8
  • Formula Weight
    583.07
  • Molecular Formula
    C20H15Br3N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(N1C2=C(N=C1Br)N(C)C(=O)N(CC3=CC=C(Br)C=C3)C2=O)C4=CC=C(Br)C=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chang Y, et al. Design, synthesis, biological evaluation, and molecular docking of 1, 7-dibenzyl-substituted theophylline derivatives as novel BRD4-BD1-selective inhibitors. Medicinal Chemistry Research, 2021, 30(8): 1453-1468.
molnova catalog
related products
  • FHD-286

    FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.

  • JQAD1

    JQAD1 is a potent and selective histone acetyltransferase EP300 degrader (PROTAC?; DC50≤ 31.6 nM); comprises an EP300 inhibitor, A485, joined by a linker to a cereblon E3 ligase ligand.

  • IRAK4-IN-1

    IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.